We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Aggressive Breast Cancer Identified with Fluorescent Technique

By LabMedica International staff writers
Posted on 21 Jul 2016
Ductal carcinoma in situ (DCIS) of the breast is the most common type of non-invasive breast cancer and in DCIS, epithelial cells proliferate within ducts, which are surrounded by a double layer of myoepithelial cells and basement membranes.

Although epidemiological studies propose aggressive and non-aggressive forms of ductal DCIS, they cannot be identified with conventional histopathology and because of this, to be safe, most patients undergo aggressive treatment.

Scientists at the University of Michigan Medical School (Ann Arbor, MI, USA) used a new method, called biomarker ratio imaging microscopy (BRIM), to evaluate the co-expression of biomarkers correlating and anti-correlating with breast cancer aggressiveness in a retrospective study of DCIS samples. More...
BRIM combines traditional microscope techniques that pathologists use to examine tissue with mathematical analysis. The technique compares levels of different biomarkers, which can be seen as different fluorescent colors in stained tissue under a microscope.

Fluorescence microscopy was performed using a TE2000-U inverted microscope (Nikon, Melville, NY, USA) and an Andor iXon camera (Andor Technology, Belfast, UK) with 100 W mercury lamp. The investigators looked at biopsy tissue samples from 23 patients with DCIS. They used fluorescent imaging, where the tissue samples are stained, to identify key biomarkers. Each biomarker was stained a different color. They then entered the images of the stained tissue samples into a computer that calculated the levels of different biomarkers in each pixel. In cancer, some biomarkers are present in high levels while others are less prolific. BRIM uses the ratio of these different levels to form an image of improved contrast.

The BRIM method found 22% of the samples had low ratios of cancer versus non-cancer biomarkers, suggesting those lesions were very slow-growing and non-aggressive. They note that an advantage of BRIM is that it uses several biomarkers rather than relying on only one. They decided which biomarkers to use after an extensive literature search. The authors concluded that the ability to stratify DCIS lesions and to identify potentially non-aggressive and aggressive lesions raises important issues in addressing overtreatment in breast cancer. BRIM is particularly attractive because it could be integrated into clinical pathology practices. Moreover, this approach may be useful in the cytologic study of aspirates in breast cancer and in peritoneal fluids in ovarian cancer. The study was published on June 1, 2016, in the journal Scientific Reports.

Related Links:
University of Michigan Medical School
Nikon
Andor Technology

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.